Table 2 Comparison of therapeutic and angiographic characteristics of study participants
Variables | MACE | Total (n = 276) | p value | |
|---|---|---|---|---|
No (n = 212) | Yes (n = 64) | |||
Treatments | 0.071† | |||
Conservative | 43 (20.3) | 20 (31.3) | 63 (22.8) | |
PCI | 83 (39.2) | 27 (42.2) | 110 (39.9) | |
CABG | 86 (40.6) | 17 (26.6) | 103 (37.3) | |
Coronary angiogram | ||||
Left main disease | 27 (12.7) | 5 (7.8) | 32 (11.6) | 0.281† |
Single-vessel disease | 82 (38.7) | 23 (35.9) | 105 (38.0) | 0.692† |
Two-vessel disease | 39 (18.4) | 17 (26.6) | 56 (20.3) | 0.155† |
Three-vessel disease | 79 (37.3) | 20 (31.3) | 99 (35.9) | 0.177† |
Discharge therapy | ||||
Beta blockers | 158 (74.5) | 42 (65.6) | 200 (72.5) | 0.162† |
ACE-I/ARB | 132 (62.) | 44 (68.8) | 176 (63.8) | 0.344† |
ASA | 199 (93.9) | 60 (93.8) | 259 (93.8) | 0.973† |
P2Y12 inhibitors | 182 (85.8) | 50 (78.1) | 232 (84.1) | 0.139† |
Statins | 196 (92.5) | 56 (87.5) | 252 (91.3) | 0.218† |
Risk scores | ||||
GRACE 2.0 | 99.0 (80.3–116.0) | 107.5 (88.5–127.3) | 100.0 (82.0–120.0) | 0.072* |
ACEF | 1.1 (0.9–1.3) | 1.3 (0.9–1.4) | 1.2 (0.9–1.3) | 0.002‡ |
SYNTAX | 14.0 (8.0–23.4) | 13.3 (7.0–26.0) | 14.0 (8.0–24.0) | 0.869‡ |
Clinical SYNTAX | 14.8 (8.6–26.9) | 15.1 (8.4–31.0) | 14.9 (8.6–27.7) | 0.462‡ |
SYNTAX II PCI | 25.5 (20.4–33.7) | 29.8 (24.1–38.5) | 26.8 (20.8–34.8) | 0.001* |
SYNTAX II CABG | 24.9 (17.2–32.0) | 27.0 (18.7–36.4) | 25.5 (18.1–33.6) | 0.038* |